GlassScriptPhysician profile
Laurence Kelley
NPI 1083676498
$2,353.37
in general payments reported to CMS, 2019-2025
25 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $272 · 2020: $270 · 2021: $112 · 2022: $82.86 · 2023: $537 · 2024: $327 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,617.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,616.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $576.80 | 2019-2025 | Camzyos, Eliquis |
| Baxter Healthcare | $253.81 | 2024-2025 | Hillrom - Carnation Ambulatory Monitor |
| Janssen Pharmaceuticals, INC | $216.68 | 2021-2023 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.37 | 2019-2025 | Lifevest |
| Amgen INC. | $170.69 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $136.23 | 2019-2025 | |
| Boston Scientific Corporation | $126.21 | 2023 | Watchman Access System |
| Novartis Pharmaceuticals Corporation | $124.39 | 2019-2025 | |
| Alnylam Pharmaceuticals INC. | $74.42 | 2025 | Amvuttra |
| Inspire Medical Systems, INC. | $66.95 | 2023-2025 | Inspire |
| Edwards Lifesciences Corporation | $55.92 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $51.67 | 2024-2025 | Opsumit |
| Sanofi-Aventis U.S. LLC | $46.47 | 2019 | |
| Novo Nordisk INC | $38.46 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Daiichi Sankyo INC. | $27.40 | 2025 | Injectafer |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $24.79 | 2024 | (Ck4) Mcot |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.49 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.76 | 2024 | Arcalyst |
| Esperion Therapeutics, INC. | $20.67 | 2025 | Nexletol |
| Astrazeneca Pharmaceuticals LP | $17.80 | 2020 | |
| Bardy Diagnostics, INC. | $16.40 | 2022 | |
| Lundbeck LLC | $15.63 | 2019 | |
| Stryker Corporation | $15.01 | 2021 | |
| Cashflow Solutions, LLC | $14.93 | 2024 | Pcd-52 737a (US) White, Pcd-51 731a (US) - White, Lympha Press Optimal Plus(US) Bt |
| Amarin Pharma, INC. | $12.42 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Kelley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.